Remimazolam during induction of anesthesia in patients with severe aortic stenosis

Remimazolam during induction of anesthesia in patients with severe aortic stenosis - Remimazolam during induction of anesthesia in patients with severe aortic stenosis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000042318

Enrollment

Registered

2020-11-04

Start date

2020-11-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe aortic stenosis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with a diagnosis of severe aortic stenosis on a preoperative transthoracic echocardiogram.

Exclusion criteria

Exclusion criteria: (1) Patients undergoing emergency surgery (2) Patients who are allergic to the study drugs (fentanyl, remifentanil, rocuronium, sugammadex, benzodiazepines, sevoflurane, desflurane) (3) Patients for whom the use of remimazolam is contraindicated (patients with acute angle-closure glaucoma, myasthenia gravis, shock, coma, and acute alcoholism with suppressed vital signs) (4) Patients with preoperative disturbance of consciousness (5) Patients who have been sedated preoperatively (6) Patients deemed inappropriate by the principal investigator/associators (excluded with reasons for exclusion)

Design outcomes

Primary

Measure	Time frame
Dosage of vasoconstrictor and inotropic agents during induction of anesthesia.	—

Secondary

Measure	Time frame
Hemodynamic change (blood pressure and heart rate). Time to loss of consciousness, time from the start of anesthesia induction to the end of tracheal intubation, total remimazolam dose, change in BIS (bispectral index) level, change in TOI (tissue oxygenation index), postoperative nausea and vomiting, incidence of postoperative delirium, presence or absence of awareness at the time of induction of anesthesia, and postoperative flumazenil use and dose.	—

Measure

Time frame

Hemodynamic change (blood pressure and heart rate). Time to loss of consciousness, time from the start of anesthesia induction to the end of tracheal intubation, total remimazolam dose, change in BIS (bispectral index) level, change in TOI (tissue oxygenation index), postoperative nausea and vomiting, incidence of postoperative delirium, presence or absence of awareness at the time of induction of anesthesia, and postoperative flumazenil use and dose.

—

Countries

Japan

Contacts

Public ContactToshiyuki Nakanishi

Nagoya City University Graduate School of Medical Sciences Department of Anesthesiology and Intensive Care Medicine

nakanishi.anest@gmail.com052-851-5511

Outcome results